Pevonedistat: all 34 studies that test it

Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.

• Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaRecruitingNCT03013998Phase 2/3
• Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid TumorTerminatedNCT04800627Phase 1/2Results posted
• A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive ChemotherapyCompletedNCT04266795Phase 2Results posted
• Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With ImmunotherapyActive, not recruitingNCT03965689Phase 2Results posted
• A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver ProblemsCompletedNCT03814005Phase 1Results posted
• Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT03813147Phase 1Results posted
• Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeTerminatedNCT03772925Phase 1Results posted
• Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to TreatmentCompletedNCT03770260Phase 1Results posted
• Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission AMLTerminatedNCT03709576Phase 2Results posted
• Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or LymphomaCompletedNCT03323034Phase 1Results posted
• Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)CompletedNCT03268954Phase 3Results posted
• Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase InhibitorsCompletedNCT03238248Phase 2Results posted
• Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung CancerTerminatedNCT03228186Phase 2Results posted
• A Study of [14 C]-Pevonedistat in Participants With Advanced Solid TumorsCompletedNCT03057366Phase 1Results posted
• A Study of Pevonedistat in Adult East Asian ParticipantsCompletedNCT02782468Phase 1Results posted
• An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)CompletedNCT02610777Phase 2Results posted
• Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or OlderCompletedNCT01814826Phase 1Results posted
• A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic SyndromesWithdrawnNCT04985656Phase 2
• Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and PevonedistatCompletedNCT04712942Phase 2
• Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous LeukemiaTerminatedNCT04172844Phase 1
• Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard ChemotherapyActive, not recruitingNCT04090736Phase 3
• Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaActive, not recruitingNCT03862157Phase 1/2
• Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaWithdrawnNCT03745352Phase 2
• Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin LymphomaActive, not recruitingNCT03479268Phase 1
• Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDSCompletedNCT03459859Phase 1
• Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With MyelofibrosisTerminatedNCT03386214Phase 1
• Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHLCompletedNCT03349281Phase 1
• Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid LeukemiaActive, not recruitingNCT03330821Phase 1/2
• Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid LeukemiaCompletedNCT03009240Phase 1
• MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell LymphomaWithdrawnNCT01415765Phase 1/2
• Dose Escalation Study of MLN4924 in Adults With MelanomaCompletedNCT01011530Phase 1
• MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic LeukemiaCompletedNCT00911066Phase 1
• Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple MyelomaCompletedNCT00722488Phase 1
• Study of MLN4924 in Adult Patients With Nonhematologic MalignanciesCompletedNCT00677170Phase 1

← Pevonedistat overview